ClinConnect ClinConnect Logo
Search / Trial NCT06763770

Digital Self-Management and Peer Mentoring Intervention

Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · Jan 2, 2025

Trial Information

Current as of November 14, 2025

Enrolling by invitation

Keywords

Pediatric Cancer Survivors Self Management Young Adults Childhood Cancer Survivors Transition Peer Mentor

ClinConnect Summary

This study tests a digital self-management program called Managing Your Health (MYH), with peer mentoring, to help young adults who survived childhood cancer manage their survivorship care as they move from pediatric to adult healthcare. In a randomized trial, participants are assigned by chance to receive the MYH program (six weekly video calls with a peer mentor plus self-management modules in a mobile app) or to usual care plus educational materials. The goal is to see if MYH can improve how well survivors take care of their long-term health and stay on track with follow-up care.

Who can join? Adults ages 18–25 who were diagnosed with cancer as children (before age 20) and completed treatment at a pediatric center at least two years ago can participate, provided they do not have significant cognitive or physical delays and can read and speak English. About 300 survivors will participate at two sites (Rutgers in New Jersey and the University of Southern California in Los Angeles). Researchers will measure outcomes at baseline, 3 months, and 12 months, focusing on self-management skills (the main outcome), adherence to guideline-recommended follow-up care, and overall quality of life. The study is currently enrolling and results are not yet available. De-identified data may be shared with qualified researchers after the study is finished.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Diagnosis with any malignant childhood cancer between the ages 0-19 at least 5 years prior
  • 2. Cancer treatment occurred at a pediatric center/facility
  • 3. Current age 18-25
  • 4. At least 2 years from treatment completion (typical time for transfer to long-term follow-up care)
  • Exclusion Criteria:
  • 1. Any documented physical or self-reported cognitive delay that could prevent self-management of health care
  • 2. Diagnoses of cancer not typically considered pediatric (I.e., melanoma, carcinoma of the breast, colorectum, lung, ovary, and testicle)
  • 3. Unable to speak/read English

About Rutgers, The State University Of New Jersey

Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.

Locations

Los Angeles, California, United States

New Brunswick, New Jersey, United States

Patients applied

0 patients applied

Trial Officials

Kristine Levonyan-Radloff, MS

Study Director

Rutgers Cancer Institute

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported